Literature DB >> 12401633

The effect of the addition of epinephrine on early systemic absorption of epidural ropivacaine in humans.

Bee B Lee1, Warwick D Ngan Kee, John L Plummer, Manoj K Karmakar, April S Y Wong.   

Abstract

UNLABELLED: The addition of epinephrine to ropivacaine has not been recommended because ropivacaine has intrinsic vasoconstrictor properties. However, few pharmacokinetic data are available on the addition of epinephrine to epidural ropivacaine in humans. In this prospective, double-blinded study, we randomized patients having elective abdominal hysterectomy to receive epidural ropivacaine 1.5 mg/kg, diluted in 15 mL, either with (epinephrine group, n = 12) or without (plain group, n = 12) epinephrine 5 microg/mL and then measured arterial and venous plasma concentrations of ropivacaine at intervals up to 180 min. We found that arterial and venous plasma ropivacaine concentrations were smaller in the epinephrine group compared with the plain group in the first 60 min after the drug administration (P < 0.01). Mean (+/- SD) maximum total plasma ropivacaine concentration was smaller in the epinephrine group (arterial, 0.92 +/- 0.32 microg/mL; venous, 0.82 +/- 0.33 microg/mL) compared with the plain group (1.31 +/- 0.39 microg/mL and 1.31 +/- 0.50 microg/mL, respectively; P = 0.01). Time to maximum total plasma ropivacaine concentration was not significantly different between groups (mean +/- SD; arterial, 16 +/- 2 min; venous, 23 +/- 2 min in the epinephrine group versus 9 +/- 2 min and 12 +/- 3 min, respectively, in the plain group; P = 0.08). Arterial plasma ropivacaine concentrations were larger than venous concentrations during the first hour (P < 0.01); the arterio-venous difference decreased exponentially, and the rate and magnitude of this decrease was unaffected by epinephrine. We conclude that the addition of epinephrine 5 microg/mL to ropivacaine reduced the early systemic plasma concentrations of ropivacaine after epidural injection and may be useful for decreasing the risk of toxicity from systemic absorption of epidural ropivacaine. IMPLICATIONS: The addition of epinephrine 5 microg/mL to epidural ropivacaine reduced the systemic arterial and venous plasma concentrations of ropivacaine in the first hour and the maximum plasma concentration of ropivacaine. Epinephrine may be a useful additive for reducing the risk of systemic toxicity when large doses of ropivacaine are given epidurally.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12401633     DOI: 10.1097/00000539-200211000-00055

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  5 in total

1.  Use of Intralipid in an infant with impending cardiovascular collapse due to local anesthetic toxicity.

Authors:  Shailesh Shah; Senthil Gopalakrishnan; Jesus Apuya; Sonia Shah; Timothy Martin
Journal:  J Anesth       Date:  2009-08-14       Impact factor: 2.078

2.  Pharmacokinetics of 450 mg ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study.

Authors:  Karin P W Schoenmakers; Tom B Vree; Nigel T M Jack; Bart van den Bemt; Jacques van Limbeek; Rudolf Stienstra
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

3.  Effects of adding epinephrine on the early systemic absorption kinetics of local anesthetics in abdominal truncal blocks.

Authors:  Masato Kitayama; Morito Wada; Hiroshi Hashimoto; Tsuyoshi Kudo; Norikazu Takada; Kazuyoshi Hirota
Journal:  J Anesth       Date:  2014-01-29       Impact factor: 2.078

4.  The effects of adding epinephrine to ropivacaine for popliteal nerve block on the duration of postoperative analgesia: a randomized controlled trial.

Authors:  Karin P W Schoenmakers; Maaike G E Fenten; Jan Willem Louwerens; Gert Jan Scheffer; Rudolf Stienstra
Journal:  BMC Anesthesiol       Date:  2015-07-10       Impact factor: 2.217

Review 5.  Update on the clinical utility and practical use of ropivacaine in Chinese patients.

Authors:  Man Li; Li Wan; Wei Mei; Yuke Tian
Journal:  Drug Des Devel Ther       Date:  2014-09-09       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.